Stocktoria
GYRE THERAPEUTICS, INC. GYRE
GYRE THERAPEUTICS, INC. (GYRE) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 6.42% (safety: no dividend). FY2025 revenue was $116.6M at a 8.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -1.85 — grey zone (between the usual thresholds). A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.571 |
| Retained earnings / assets | -0.512 |
| EBIT / assets | 0.052 |
| Equity / liabilities | 1.99 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| GYRE | GYRE THERAPEUTICS, INC. | 3/9 | 4.52 | 71 | +10.2% |
| ASRT | Assertio Holdings, Inc. | 2/9 | -6.37 | — | -5% |
| URGN | UroGen Pharma Ltd. | 1/9 | -15.59 | — | +21.4% |
| XNCR | Xencor Inc | 3/9 | 2.23 | — | +13.7% |
| TBPH | Theravance Biopharma, Inc. | 6/9 | 0.96 | 8.6 | +66.9% |
| ZVRA | ZEVRA THERAPEUTICS, INC. | 5/9 | -0.84 | 9 | +350.9% |
| ZYME | Zymeworks Inc. | 5/9 | -3.24 | — | +38.9% |
About GYRE THERAPEUTICS, INC.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
FAQ
Is GYRE financially healthy?
GYRE THERAPEUTICS, INC.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does GYRE pay a dividend, and is it safe?
Yes. GYRE THERAPEUTICS, INC. pays a dividend yielding about 6.42% with a None payout ratio, rated “no dividend” for safety.
How profitable is GYRE?
In FY2025, GYRE THERAPEUTICS, INC. had a net margin of 8.5% and a return on equity of 15.8%.
What is GYRE's P/E ratio?
GYRE THERAPEUTICS, INC.'s trailing price-to-earnings (P/E) ratio is about 71.0×, based on its latest annual earnings.
What is the analyst price target for GYRE?
The average Wall-Street price target for GYRE THERAPEUTICS, INC. is $18.67, about 180.3% above the recent price, from 3 analysts.
Is GYRE a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on GYRE THERAPEUTICS, INC.: a Piotroski F-score of 3/9, an Altman Z″ in the safe zone, a P/E of about 71.0×, a dividend yield of 6.42%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.